Loading...
Nanoparticles for co-delivery of Osimertinib and Selumetinib to Overcome Osimertinib-acquired Resistance in Non-small Cell Lung Cancer
Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients who are resistant to first-generation EGFR TKIs...
Saved in:
| Published in: | Acta Biomater |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8273131/ https://ncbi.nlm.nih.gov/pubmed/34048974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.actbio.2021.05.018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|